Back to Search
Start Over
Off-label uses of TNF-a inhibitors and IL-12/23 inhibitors in dermatology
- Source :
- Dermatology Online Journal; vol 27, iss 11
- Publication Year :
- 2021
-
Abstract
- TNF-a inhibitors, which include adalimumab, infliximab, etanercept, certolizumab, and golimumab, and IL-12/23 inhibitor, ustekinumab, have been widely used as a U.S. Food and Drug Administration (FDA) approved for the treatment of psoriasis. Outside of psoriasis, high levels of TNF-a had also been found in several skin diseases including hidradenitis suppurativa. IL-12 and IL-23 play important role in the pathogenesis of SLE, alopecia areata, and vitiligo. This paper reviews the off-label uses of TNF-a inhibitors and IL-12/23 inhibitors in skin disorders.
Details
- Database :
- OAIster
- Journal :
- Dermatology Online Journal; vol 27, iss 11
- Notes :
- application/pdf, Dermatology Online Journal vol 27, iss 11
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1298734548
- Document Type :
- Electronic Resource